Tesamorelin (Egrifta): The FDA-Approved GHRH Analog
Tesamorelin
37% Liver Fat Reduction
In a randomized, double-blind trial, tesamorelin reduced hepatic fat fraction by a relative 37 percent over 12 months in people with HIV and nonalcoholic fatty liver disease, with 35 percent of treated patients achieving normal liver fat levels.
Stanley et al., The Lancet HIV, 2019
Stanley et al., The Lancet HIV, 2019
View as imageTesamorelin is the only growth hormone releasing hormone (GHRH) analog with FDA approval for a therapeutic indication. Approved in November 2010 under the brand name Egrifta for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, tesamorelin works by stimulating the pituitary gland to release endogenous growth hormone rather than delivering GH directly. This mechanism places it upstream of recombinant GH therapy, preserving the body's own regulatory feedback loops while achieving targeted fat reduction. Makimura et al. documented in 2014 that tesamorelin significantly increased GH and IGF-1 levels while reducing visceral adipose tissue and improving lipid profiles in HIV-infected patients, establishing the metabolic scope of its effects beyond simple fat reduction.[1] Since its approval, tesamorelin has generated unexpected research interest in two areas far removed from its original indication: nonalcoholic fatty liver disease and cognitive decline. For how tesamorelin fits within the broader GHRH signaling landscape, see Sermorelin: The Original Growth Hormone Releasing Peptide and for the downstream pathway it activates, see CJC-1295 and IGF-1: What the Research Shows About Elevation. For deep dives into each application, see Tesamorelin and HIV Lipodystrophy: Why It Was Developed, Tesamorelin and Liver Fat: MASH Research Beyond Its Approved Use, and Tesamorelin's Cognitive Effects: An Unexpected Finding.
Key Takeaways
- Tesamorelin reduced visceral adipose tissue by approximately 15 to 18 percent versus placebo over 26 weeks in Phase III trials for HIV-associated lipodystrophy, leading to FDA approval in 2010
- Hepatic fat fraction declined by a relative 37 percent with tesamorelin versus placebo over 12 months in an HIV NAFLD trial, with 35 percent of treated patients normalizing liver fat versus 4 percent on placebo (Stanley et al., The Lancet HIV, 2019)
- Tesamorelin improved executive function (response inhibition and set-shifting) in both healthy older adults and those with mild cognitive impairment over 20 weeks (Baker et al., Archives of Neurology, 2012)
- Visceral fat re-accumulates to near baseline levels within weeks of discontinuing tesamorelin, indicating that chronic therapy is necessary to maintain reductions
- GHRH agonist MR-409 protected against acute lung injury in preclinical models, suggesting anti-inflammatory properties of GHRH pathway activation (Louzada et al., 2023)
- The GHRH-GH-IGF-1 axis regulates metabolism, immunity, and tissue repair beyond growth, expanding the therapeutic rationale for GHRH analogs (Jain et al., Endocrine Reviews, 2013)
Mechanism: How Tesamorelin Stimulates Growth Hormone
Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification increases the peptide's stability and resistance to enzymatic degradation without altering its receptor binding properties. The peptide binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering intracellular cAMP signaling that culminates in growth hormone release.
Unlike recombinant GH (somatropin), which delivers a bolus of exogenous hormone and bypasses hypothalamic-pituitary regulation, tesamorelin works within the existing feedback architecture. The pituitary still responds to somatostatin inhibition, and IGF-1 negative feedback remains intact. This means tesamorelin-induced GH release follows a more physiological pattern than direct GH injection.
Jain et al. reviewed the pathophysiology of the GHRH-GH-IGF-1 axis in 2013, documenting how this cascade regulates not just growth but metabolism, body composition, and immune function throughout life.[3] GH release from tesamorelin stimulation increases lipolysis (fat breakdown) in visceral adipose tissue, increases lean body mass, and raises circulating IGF-1. The selective effect on visceral versus subcutaneous fat is one of the compound's most clinically relevant properties.
Dieguez et al. provided updated understanding of hypothalamic GHRH biology in 2025, confirming that GHRH neurons integrate metabolic, circadian, and stress signals to regulate GH secretion, and that GHRH analog therapy engages this entire integration network rather than simply pushing one button.[7]
FDA-Approved Indication: HIV-Associated Lipodystrophy
The Problem
Antiretroviral therapy (ART) for HIV, while life-saving, causes metabolic complications in a significant proportion of patients. HIV-associated lipodystrophy involves abnormal fat redistribution: loss of subcutaneous fat in the face and limbs (lipoatrophy) combined with accumulation of visceral fat in the abdomen (lipohypertrophy). The visceral fat accumulation is not merely cosmetic. It is associated with a 2 to 3 fold increased cardiovascular risk, insulin resistance, dyslipidemia, and systemic inflammation. Older protease inhibitor regimens were the primary culprits, but lipodystrophy persists even with newer ART regimens, affecting an estimated 20 to 35 percent of people on long-term treatment.
Before tesamorelin, patients with HIV-associated lipohypertrophy had limited options: switch ART regimens (which may compromise viral suppression), use recombinant GH (which is not FDA-approved for this indication and has different metabolic effects), or pursue surgical liposuction (which does not address the underlying metabolic abnormality). The need for a targeted medical therapy drove tesamorelin's development.
Phase III Trial Results
Two multicenter, randomized, double-blind, placebo-controlled Phase III trials enrolled HIV-infected patients with lipodystrophy and excess abdominal fat. Each trial had a 26-week Main Phase followed by a 26-week Extension Phase.
In the Main Phase, patients receiving tesamorelin 2 mg subcutaneously once daily showed approximately 15 to 18 percent reduction in visceral adipose tissue (measured by CT scan) compared to placebo. Patients also showed increased lean body mass, decreased waist circumference, and improvements in body image scores.
The Extension Phase revealed a critical limitation: patients who were switched from tesamorelin to placebo after 26 weeks demonstrated re-accumulation of visceral fat to near baseline levels. This means tesamorelin is a maintenance therapy, not a cure. Continuous treatment is required to sustain fat reduction. Makimura et al. confirmed in their 2014 analysis that tesamorelin's metabolic benefits, including improved triglycerides and reduced trunk fat, depend on continued administration.[1]
Safety Profile
The most commonly reported adverse reactions include arthralgia (joint pain), injection site reactions (erythema, pruritus, pain), pain in extremity, peripheral edema, and myalgia. Tesamorelin is contraindicated during pregnancy due to potential interference with fetal growth. It should not be used in patients with active malignancy, as GH can promote tumor growth. In clinical trials, injection site reactions occurred in approximately 8 to 13 percent of patients.
Formulation Evolution
The original formulation (Egrifta SV) required reconstitution before each injection. In 2024, the FDA approved a new F8 formulation marketed as Egrifta WR (weekly reconstitution), which simplifies the preparation process. This reformulation reflects the practical reality that daily self-injection of a peptide requiring reconstitution creates adherence barriers.
Beyond HIV: Liver Fat and NASH/MASH
The most striking off-label research finding for tesamorelin involves nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction-associated steatotic liver disease (MASLD/MASH).
In a randomized, double-blind, multicenter trial published in The Lancet HIV in 2019, 61 adults with HIV and NAFLD received tesamorelin 2 mg daily or placebo for 12 months. The primary outcome was dramatic: hepatic fat fraction declined by 4.1 percentage points in the tesamorelin group but remained unchanged in the placebo group (P = 0.018), representing a relative reduction of 37 percent. In the tesamorelin group, 35 percent of patients normalized their liver fat to below 5 percent, compared to just 4 percent on placebo (P = 0.007).
Critically, tesamorelin also prevented fibrosis progression. Among patients with baseline NASH (33 percent of the cohort), liver histology improved in the treatment group. Follow-up transcriptomic analysis published in JCI Insight showed that tesamorelin altered hepatic gene expression profiles related to lipid metabolism and fibrogenesis, suggesting the liver effects are not simply downstream of visceral fat reduction.
These findings have generated interest in tesamorelin as a potential MASH therapy beyond the HIV population. Given the lack of effective MASH treatments and the massive global burden of the disease, a GH-releasing peptide that reduces liver fat by 37 percent and prevents fibrosis progression represents a significant therapeutic lead. However, no Phase III trial in non-HIV MASH has been completed, and the HIV-specific metabolic context may not generalize. For other peptide approaches to liver disease, see Retatrutide and Liver Fat: The Surprising MASH Connection. For more on tesamorelin's liver effects specifically, see Tesamorelin and Liver Fat: MASH Research Beyond Its Approved Use.
Cognitive Effects: An Unexpected Discovery
Baker et al. conducted a randomized, controlled trial of GHRH (tesamorelin) in 152 adults aged 55 to 87, including 66 with mild cognitive impairment (MCI), administering 1 mg daily subcutaneously for 20 weeks.[2]
The cognitive findings were surprising. In both healthy older adults and those with MCI, tesamorelin improved executive function, specifically response inhibition (Stroop Color Word Interference test, P = 0.009) and cognitive set-shifting (Task Switching, P = 0.01). Working memory showed a trend toward improvement (P = 0.07). For adults with MCI specifically, tesamorelin significantly improved delayed verbal recall, a finding not observed in the healthy aging group.
The mechanism appears to involve IGF-1-mediated effects on brain function. Tesamorelin increased plasma IGF-1 levels (P less than 0.0001) while keeping them within physiological range. IGF-1 crosses the blood-brain barrier and has well-documented neuroprotective and neurotrophic effects, including promotion of neuronal survival, synaptic plasticity, and neurogenesis in the hippocampus.
Follow-up brain imaging using magnetic resonance spectroscopy showed that 20 weeks of GHRH administration increased GABA levels in three brain regions (frontal cortex, posterior cingulate, and lenticular nucleus), increased N-acetylaspartylglutamate (NAAG) in the frontal cortex, and decreased myo-inositol (a marker of neuroinflammation and glial activation) in the posterior cingulate. These neurochemical changes provide a biological basis for the cognitive improvements and suggest that GHRH analog therapy may reduce neuroinflammation while enhancing inhibitory neurotransmission.
The cognitive findings are particularly significant given the aging HIV population. As antiretroviral therapy has transformed HIV from a fatal to a chronic disease, HIV-associated neurocognitive disorder (HAND) has emerged as a major clinical concern. The intersection of aging-related cognitive decline and HIV-associated neuroinflammation creates a population that may be especially responsive to GHRH-mediated neuroprotection.
A Phase II trial (NCT02572323) has investigated tesamorelin for cognition in aging HIV-infected persons specifically, exploring whether the dual burden of HIV-associated neurocognitive disorder and age-related decline might make this population particularly responsive. For detailed coverage of this research direction, see Tesamorelin's Cognitive Effects: An Unexpected Finding.
The GHRH Agonist Platform: Beyond Tesamorelin
Tesamorelin is not the only GHRH agonist under investigation. The broader GHRH agonist research platform has revealed biological effects that extend well beyond fat metabolism and growth.
Anti-Inflammatory Properties
Barabutis et al. documented in 2018 that GHRH signaling intersects with p53-mediated inflammation pathways, suggesting that GHRH agonists may have direct anti-inflammatory effects independent of GH release.[4] Louzada et al. demonstrated in 2023 that the GHRH agonist MR-409 protected against acute lung injury in preclinical models through anti-inflammatory mechanisms, opening a therapeutic avenue entirely unrelated to growth or metabolism.[6]
Metabolic Regulation
Leone et al. reviewed the broader metabolic roles of GHRH in 2020, documenting how GHRH receptors are expressed not just in the pituitary but in peripheral tissues including adipose tissue, liver, and pancreas, enabling direct tissue-level effects of GHRH analogs.[5] Steenblock et al. explored GHRH's role specifically in diabetes and metabolic disease in 2025, noting that GHRH agonists affect pancreatic beta-cell function and insulin sensitivity through mechanisms distinct from GH elevation.[10]
Tissue Protection
Dulce et al. reviewed GHRH signaling in tissue protection and repair in 2025, documenting how GHRH agonists promote cell survival and reduce apoptosis in cardiac, neural, and pulmonary tissues.[8] Sigdel et al. explored GH-releasing hormone's role in tissue regeneration in 2025, providing evidence that GHRH analogs may enhance wound healing and tissue repair through IGF-1-dependent and IGF-1-independent pathways.[9]
These findings collectively suggest that GHRH agonists like tesamorelin are not simply tools for manipulating GH levels. The GHRH receptor itself appears to mediate tissue-protective effects that are partially or fully independent of circulating GH and IGF-1. This has significant implications for tesamorelin's therapeutic potential: the liver fat reduction, cognitive improvement, and anti-inflammatory effects observed in clinical trials may reflect direct GHRH receptor activation in peripheral tissues and the brain, not just the downstream consequences of elevated GH. If this hypothesis is confirmed, GHRH analogs could have therapeutic applications in conditions where GH itself is contraindicated or undesirable, such as in patients with diabetes or cancer risk factors. The GHRH pathway is increasingly recognized as a regulatory system with broader physiological reach than its name suggests.
Tesamorelin vs. Other GH-Axis Peptides
| Feature | Tesamorelin | Sermorelin | CJC-1295 | MK-677 |
|---|---|---|---|---|
| Class | GHRH analog | GHRH(1-29) | GHRH analog + DAC | Non-peptide GH secretagogue |
| FDA status | Approved (HIV lipo) | Discontinued (2008) | Not approved | Not approved |
| Route | Subcutaneous daily | Subcutaneous daily | Subcutaneous weekly | Oral daily |
| Half-life | ~26 minutes | ~11 minutes | ~8 days (with DAC) | ~5 hours |
| Mechanism | Pituitary GHRH-R | Pituitary GHRH-R | Pituitary GHRH-R | Ghrelin receptor (GHS-R1a) |
| Key advantage | Only FDA-approved GHRH | Shorter, well-studied | Long-acting | Oral availability |
| Key limitation | HIV indication only | Commercially unavailable | No clinical trials | Not FDA-approved |
Tesamorelin's advantage over sermorelin is its longer GHRH sequence (44 amino acids vs. 29) and the trans-3-hexenoic acid modification that improves metabolic stability and resistance to dipeptidyl peptidase IV (DPP-IV) cleavage. Its advantage over CJC-1295 and MK-677 is regulatory: it has Phase III trial data, FDA approval, and post-marketing safety surveillance. The comparison with MK-677 (Ibutamoren) is particularly relevant because MK-677 works through the ghrelin receptor rather than the GHRH receptor, engaging a fundamentally different pathway. For how GH peptides affect sleep architecture, see How Growth Hormone Peptides Affect Sleep Quality: The Evidence.
Evidence Gaps and Open Questions
MASH in non-HIV populations. The 37 percent liver fat reduction is compelling, but all data come from HIV-infected patients whose metabolic dysfunction has specific characteristics. Whether tesamorelin achieves similar results in the general MASH population, which represents a far larger therapeutic market, is the most commercially and clinically significant unanswered question.
Long-term cognitive outcomes. The Baker et al. cognitive trial lasted 20 weeks. Whether longer treatment produces sustained cognitive benefit, and whether it delays progression from MCI to dementia, would require multi-year trials with clinical endpoints rather than cognitive test scores.
Cancer safety. GH and IGF-1 can promote growth of existing malignancies. Long-term safety data regarding cancer incidence in tesamorelin-treated patients are limited. The contraindication in active malignancy is appropriate, but whether chronic IGF-1 elevation from tesamorelin increases cancer risk over years to decades requires ongoing surveillance. This concern is particularly relevant for the HIV population, which already has elevated rates of certain cancers (Kaposi sarcoma, non-Hodgkin lymphoma, cervical cancer) due to immune dysregulation.
Glucose metabolism. Tesamorelin increases GH, which is a counter-regulatory hormone that opposes insulin action. Clinical trials showed modest increases in fasting glucose and HbA1c in some patients. Whether this diabetogenic effect offsets the metabolic benefits of visceral fat reduction in patients with pre-existing insulin resistance is a nuanced clinical question. The net metabolic impact likely depends on the individual patient's baseline metabolic status.
Comparison with direct GH therapy. No head-to-head trial has compared tesamorelin to somatropin for HIV-associated lipodystrophy. Recombinant GH at supraphysiological doses was shown to reduce visceral fat in this population, but with more pronounced effects on glucose metabolism and lean body mass. Whether the physiological GH release pattern from tesamorelin produces different long-term metabolic outcomes than direct GH injection remains untested.
Cost and access. Tesamorelin costs approximately $5,000 to $8,000 per month without insurance coverage. Its FDA-approved indication is narrow (HIV lipodystrophy), and insurance coverage for off-label uses (MASH, cognitive decline) is generally unavailable. This cost barrier limits both clinical adoption and the feasibility of large-scale research trials.
Combination with exercise. An ongoing clinical trial (NCT06554717) is evaluating tesamorelin as an adjunct to exercise, testing whether the combination produces additive or synergistic effects on body composition and metabolic health. This pragmatic question has direct clinical relevance for how tesamorelin might be used in practice.
The Bottom Line
Tesamorelin is the only FDA-approved GHRH analog, indicated for HIV-associated lipodystrophy since 2010. It reduces visceral fat by 15 to 18 percent through stimulation of endogenous GH release from the pituitary. Beyond its approved indication, tesamorelin reduced liver fat by a relative 37 percent in a randomized HIV-NAFLD trial and improved executive function in a controlled trial of older adults with and without mild cognitive impairment. The broader GHRH agonist research platform has revealed anti-inflammatory, tissue-protective, and metabolic regulatory properties that extend well beyond fat reduction. Key limitations include the need for continuous treatment (fat re-accumulates on discontinuation), high cost, and the absence of Phase III data for liver and cognitive indications in non-HIV populations.